uniQure N.V.
Key Metrics
- Previous Close
- $20.78
- 52-Week Range
- $8.73 – $51.72
- Market Cap
- $1.42B
- P/E (TTM)
- —
- EPS (TTM)
- -3.51
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 4.83
- PEG Ratio
- —
- Return on Equity
- -88.99%
- Return on Assets
- -13.70%
- Gross Margin
- 0.00%
- Operating Margin
- -993.96%
- Profit Margin
- 0.00%
- Current Ratio
- 11.52
- Debt/Equity
- 1.90
- Total Debt
- $559.64M
- Free Cash Flow
- $-167.19M
- Revenue Growth
- 40.40%
- Earnings Growth
- —
- Enterprise Value
- $1.31B
Market Snapshot
About
uniQure is a Netherlands-based gene therapy biotechnology company focused on developing treatments for patients with severe genetic diseases. The company has a leading hemophilia B gene therapy candidate and a pipeline targeting other rare disorders. uniQure combines proprietary adeno-associated virus (AAV) technology with clinical development expertise to advance potentially curative one-time treatments.